Efficacy comparison of neoadjuvant chemotherapy, chemoradiotherapy, and chemoimmunotherapy in resectable esophageal squamous cell carcinoma: short- and long-term outcomes from a propensity score-matched analysis.
Adding radiation and immunotherapy to chemotherapy improves survival chances for advanced esophageal cancer patients compared to chemotherapy alone.
This study consecutively enrolled patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) treated at Fujian Medical University Union Hospital and Gaozhou People's Hospital between January 1, 2,019, and January 1, 2022. One-year RFS was significantly lower in the nCT group than in the nCRT and nICT groups (p = 0.
What the study was
- Study design
- Retrospective cohort study
- Population
- Patients with (see abstract)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Frontiers in medicine
Why it surfaced
Design: Retrospective cohort study; Topics: Novel therapeutics: immunotherapy, CAR-T, targeted therapy; Species: human. Score=6/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.